Clinical trials: Irinotecan
Metastatic Colorectal Cancer
CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC
The objective is to compare the efficacy and safety of CAPOXIRI+BEV therapy versus FOLFOXIRI+BEV therapy as first-line therapy in patients with metastatic colorectal cancer (mCRC).
- Trial name
- QUATTRO-II (NCT04097444)
- Testing
- Bevacizumab, 5-fluorouracil, Leucovorin calcium
- Where
- Japan
- Volunteers
- 112 people
- Sponsor
- Chugai Pharmaceutical
Small Cell Lung Cancer
Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer
This is a 2-part, multicenter, open-label, randomized study of dinutuximab and irinotecan versus irinotecan alone in subjects with relapsed or refractory small cell lung cancer (SCLC).
- Trial name
- NCT03098030
- Testing
- Dinutuximab, Irinotecan, Topotecan
- Where
- 226 sites in United States, Australia and 21 more
- Volunteers
- 483 people
- Sponsor
- United Therapeutics
Metastatic Colorectal Cancer
Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer
In Patients with metastatic colorectal cancer the following treatments first-line Folfiri+Cetuximab first-line Folfox6 + Cetuximab will be concerning efficacy and safety.
- Trial name
- NCT00286130
- Testing
- Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan, FOLFOX 6, FOLFIRI
- Where
- 27 sites in Austria, Bosnia and Herzegovina and 11 more
- Volunteers
- 150 people
- Sponsor
- Central European Cooperative Oncology Group
Colorectal Carcinoma
Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy
The purpose of this study is to determine safety and local tumor control of Embozene TANDEM Microspheres (40um TANDEM) loaded with Irinotecan to treat metastatic colorectal carcinoma (mCRC).
- Trial name
- MIRACLEIII (NCT02694562)
- Testing
- 40um Embozene TANDEM Microspheres
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Boston Scientific Corporation
Gastric Cancer, Unresectable
Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients
The primary objective of this study is to determine the efficacy of an Oxaliplatin / Irinotecan / Bevacizumab therapy followed by Docetaxel / Bevacizumab therapy followed by Bevacizumab until progression in the treatment of…
- Trial name
- NCT00952003
- Testing
- Oxaliplatin, Irinotecan, Bevacizumab, Docetaxel
- Where
- 7 sites in Austria
- Volunteers
- 40 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Small Cell Lung Cancer
Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC
This study involves being treated initially with a combination of drugs called irinotecan and cisplatin (induction therapy), followed by treatment with a drug called Gleevec (maintenance therapy).
- Trial name
- NCT00156286
- Testing
- Gleevec
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Michigan Rogel Cancer Center
Peritoneal Cancer, Pseudomyxoma Peritonei
Phase I Trial HIPEC With Nal-irinotecan
The purpose of this study is to assess the effectiveness and safety of intraperitoneal administration of heated nanoliposomal Irinotecan in cytoreductive surgery (CRS), which is surgery designed to remove as much of the cancer as…
- Conditions
- Peritoneal Cancer, Pseudomyxoma Peritonei, Mucinous Adenocarcinoma, Mucinous Tumor
- Trial name
- NCT04088786
- Testing
- nanoliposomal irinotecan
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Stony Brook University
Colorectal Cancer, Nausea and Vomiting
Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
RATIONALE: Aprepitant, palonosetron, and dexamethasone may help lessen or prevent nausea and vomiting in patients receiving chemotherapy.
- Trial name
- NCT00381862
- Testing
- aprepitant, dexamethasone, fluorouracil
- Where
- 6 sites in United States
- Volunteers
- 54 people
- Sponsor
- OHSU Knight Cancer Institute
Neuroblastoma
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
This is a phase II study looking at patient response to treatment with the combination dinutuximab, temozolomide, irinotecan, and GM-CSF.
- Trial name
- NCT06450041
- Testing
- Universal Donor (UD) TGFβi NK Cells, Temozolomide, Irinotecan
- Where
- 13 sites in United States
- Volunteers
- 62 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Cancer
Study of Irinotecan on a Weekly Schedule in Children
The medicine being offered in this study is called Irinotecan. Irinotecan has been effective against many animal cancers. It has been given to both adults and children.
- Trial name
- NCT00062842
- Testing
- Irinotecan
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Baylor College of Medicine
Colorectal Cancer Metastatic, Liver Metastasis Colon Cancer
Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease
Non-commercial, prospective, randomized, multicenter, national, phase II, open-label comparative clinical trial. The patients will be randomized in a 1: 1 ratio in two arms: Control arm.
- Trial name
- LIVERPEARL (NCT04595266)
- Testing
- FOLFOX regimen, Anti-EGFR or Bevacizumab, LIVERPEARLS-Irinotecan
- Where
- 8 sites in Spain
- Volunteers
- 48 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Colorectal Cancer
PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence
The association of doublet chemotherapy (FOLFOX and FOLFIRI) and anti-EGFR-moAbs (panitumumab or cetuximab) is a standard option for the first-line treatment of unresectable RAS and BRAF wt mCRC patients, especially with…
- Trial name
- PARERE (NCT04787341)
- Testing
- Regorafenib, Panitumumab
- Where
- Italy
- Volunteers
- 213 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Metastatic Colorectal Cancer, Colorectal Neoplasms
Resection Observatory
Primary Objective: -Evaluate the resection rate (R0/R1) in current practice for aflibercept in combination with irinotecan plus 5-fluorouracil (FOLFIRI) in patients treated for metastatic colorectal cancer (mCRC) after failure of…
- Trial name
- NCT05178745
- Testing
- Fluorouracil, Aflibercept, Irinotecan
- Volunteers
- 140 people
- Sponsor
- Sanofi
Gastro-Intestinal Cancer
Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)
The purpose of this study is to determine a safe and maximum tolerable dose of Brivanib when combined with standard dose 5FU/LV and FOLFIRI.
- Trial name
- NCT01046864
- Testing
- 5-FU, Leucovorin, Irinotecan
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 49 people
- Sponsor
- Bristol-Myers Squibb
Locally Advanced Rectal Cancer
A Study of Chinese Herbal Compound Dendrobium Huoshanense Granules in NCRT for Patients With Locally Advanced Rectal Cancer
The study evaluates the addition of Chinese Herbal Compound Dendrobium Huoshanense Granules to capecitabine and irinotecan in neoadjuvant chemoradiation(CRT) in locally advanced rectal cancer.
- Trial name
- NCT04394598
- Testing
- Dendrobium Huoshanense Granules, Pelvic Radiation, Capecitabine
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Fudan University
Metastatic Pancreatic Cancer
Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer
Study Part 1: To assess the safety and tolerability, and to characterize the pharmacokinetics (PK) of BAX2398 in combination with 5-FU/calcium levofolinate in Japanese patients.
- Trial name
- NCT02697058
- Testing
- BAX2398 + 5-FU/calcium levofolinate, 5-FU/calcium levofolinate
- Where
- 16 sites in Japan
- Volunteers
- 84 people
- Sponsor
- Institut de Recherches Internationales Servier
Colorectal Cancer
Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab.
Italian, multicentre, non comparative trial in patients with advanced Colorectal Cancer(CRC)and KRAS wild-type, defined by molecular evaluation.
- Trial name
- NCT01068132
- Testing
- Cetuximab, FOLFIRI
- Where
- 7 sites in Italy
- Volunteers
- 54 people
- Sponsor
- Regione Lombardia
Colon Cancer
Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)
This study is a prospective, open-label, randomized phase 3 clinical trial. It aims to investigate if the early introduction of intensified chemotherapy (3 months of modified FOLFIRINOX) improves the 3-year disease-free survival…
- Trial name
- CLAUDIA (NCT05534087)
- Testing
- mFOLFIRINOX-FOLFIRI intensified chemotherapy, FOLFOX or CAPOX adjuvant chemotherapy
- Where
- 13 sites in South Korea
- Volunteers
- 236 people
- Sponsor
- Seoul National University Hospital
Hepatoblastoma, Pediatric Cancer
Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma in Children
This study is a single-cohort study. Pediatric patients with advanced, relapsed/refractory hepatoblastoma who have previously failed first-line or higher systemic therapy will receive 2 cycles of treatment with sintilimab…
- Trial name
- NCT07188311
- Testing
- Pucotenlimab ,Lenvatinib
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Metastatic Colorectal Cancer
An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in Metastatic Colorectal Cancer (mCRC)
The purpose of this study is to examine the correlation between UGT1A1 genotypes and the efficacy of CPT-11 based regimens (FOLFIRI, CPT-11+S-1, CPT-11) for patients with metastatic colorectal cancer.
- Trial name
- NCT01039506
- Testing
- CPT-11 based regimens
- Where
- Japan
- Volunteers
- 1,376 people
- Sponsor
- Daiichi Sankyo Co., Ltd.